Enver VARDAR, Mehmet YILDIRIM, Olçun Ümit ÜNAL, ürker ACAR, Ufuk VARDAR

Effective Treatment of Undiferentiated Pleomorphic Sarcoma Using Gemcitabine: A Case Report

Undifferentiated pleomorphic sarcoma (UPS) is most frequently observed in the extremities but rarelyin the retroperitoneum. The present treatment for patients with metastatic or unresectable UPS in thefirst-line setting includes doxorubicin administration with or without ifosfamide. We present a case ofa 68-year-old woman who presented with a retroperitoneal giant mass. The patient underwent surgery,the mass was removed, and the final diagnosis was UPS. The postoperative stage included soft tissuemetastases. After three cycles of gemcitabine chemotherapy, computed tomography findings revealed theabsence of soft tissue metastases. The patient has remained on regular follow-up over the past two yearssince chemotherapy with no symptoms of disease recurrence. The findings of this case demonstrate thatpatients with retroperitoneal UPS may benefit from single-agent gemcitabine chemotherapy.

PDF

___

1. Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol 2018;29(4):857–71.
2. Besiroglu M, Dane F, Ciltas A, Benekli M. Systemic chemotherapy of advanced soft tissue sarcomas. J Onc Sci 2017;3(2):66–70.
3. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995;22(4 Suppl 11):42–6.
4. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000;45(2):177–81.
5. Svancárová L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(4):556–9.
6. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978;41(6):2250– 66.
7. Kajihara I, Maeda S, Yamada S, Izumi K, Masuguchi S, Fukushima S, et al. Biweekly gemcitabine therapy induces complete remission in cutaneous angiosarcoma resistant to multiple anticancer drugs. J Dermatol 2015;42(12):1197–8.
8. Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 2006;29(1):59–61.
9. Ferraresi V, Ciccarese M, Cercato MC, Nuzzo C, Zeuli M, Di Filippo F, et al. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a monoinstitutional phase II study. Cancer Chemother Pharmacol 2008;63(1):149–55.